Northwire Canada EditionSaturday, October 17, 2026
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Hydreight closes $15-million bought deal

NURS · Price

Executive Summary

  • Hydreight Technologies Inc. has closed an oversubscribed $15 million bought deal private placement led by Canaccord Genuity Corp. and Beacon Securities Ltd.
  • The company issued 3,705,000 units at $4.05 per unit, raising gross proceeds of $15,005,250, following the full exercise of the underwriters' over-allotment option.
  • Net proceeds will be used to support sales growth, expand pharmacy production lines, and fund working capital and general corporate purposes.

Key Details

  • Transaction Structure: Closed bought deal private placement with Canaccord Genuity Corp. (lead underwriter/sole bookrunner) and Beacon Securities Ltd.
  • Gross Proceeds: $15,005,250.
  • Units Issued: 3,705,000 units.
  • Price Per Unit: $4.05.
  • Underwriter Option: The underwriters exercised their option to purchase an additional 1,235,000 units in full (originally up to 1,235,000 units over the base of 2,470,000 units).
  • Warrant Terms: Each unit consists of one common share and one-half of one common share purchase warrant.
    • Exercise Price: $5.27 per warrant share.
    • Term: 24 months from the closing date.
  • Underwriter Compensation:
    • Cash commission: $900,315.
    • Broker warrants: 222,300 non-transferable warrants exercisable at $4.05 per share for 24 months.
  • Use of Proceeds: Sales growth, creating/expanding existing pharmacy production lines, working capital, and general corporate purposes.
  • Regulatory Basis: Listed issuer financing exemption under National Instrument 45-106; exemptions under the US Securities Act of 1933.
  • Hold Period: No hold period applies to the units or warrant shares under applicable Canadian securities laws.

Notable Quotes

  • "This financing was oversubscribed within hours of announcement, reflecting strong conviction in Hydreight's execution and the durability of our model." — Shane Madden, CEO
  • "The addition of multiple new high-quality institutional investors at this stage meaningfully and strategically bolsters our share register while providing further validation of our platform and is an important step as we scale." — Shane Madden, CEO
Read the original news release →

More from Hydreight Technologies Inc